A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202)
in patients with previously treated RAS mutant advanced or metastatic CRC. All patients will
receive treatment with FOLFIRI and bevacizumab. In addition, patients will be randomized to
receive either ompenaclid 3000 mg BID or matching placebo (herein referred to as Study Drug).
Each treatment cycle is 28 days in duration.